mirvetuximab soravtansine

01/01/2019 - "IMGN853 is currently being evaluated in multiple clinical trials, in which the immunohistochemical evaluation of an archival tumor or biopsy specimen is used for patient screening. "
11/01/2017 - "Concordance of FRα expression in biopsy versus archival tumor samples suggests that archival tissue can reliably identify patients with receptor-positive tumors and is appropriate for patient selection in mirvetuximab soravtansine clinical trials. "
08/15/2017 - "In this phase 1 dose-escalation study, the authors investigated IMGN853 in patients with FRα-positive solid tumors. "
12/12/2022 - "Mirvetuximab soravtansine (Elahere) for ovarian, fallopian tube, and primary peritoneal cancer."
01/01/2019 - "The correlation between 89Zr-M9346A tumor uptake and treatment response using IMGN853 in FRαhigh TNBC PDX model suggested the potential of 89Zr-M9346A PET as a noninvasive tool to prescreen patients based on the in vivo PET imaging for IMGN853-targeted treatment."

07/01/2023 - "This meta-analysis aims to systematically analyze the efficacy and toxicity of mirvetuximab soravtansine (MIRV) as second-line and above treatment for advanced or recurrent ovarian cancer. "
07/15/2020 - "Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer."
01/01/2018 - "Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. "
08/15/2017 - "IMGN853 demonstrated a manageable safety profile and encouraging preliminary clinical activity, particularly in patients with ovarian cancer. "
08/18/2023 - "Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations."

07/01/2018 - "Here we describe the rationale and design of FORWARD I (NCT02631876), the first randomized, multicenter Phase III study to compare the safety and efficacy of mirvetuximab soravtansine versus investigator's choice of chemotherapy in women with folate receptor-α-positive, platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer. "

07/01/2023 - "Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer."
11/01/2017 - "Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine."
01/01/2019 - "Mirvetuximab Soravtansine, IMGN853, is an ADC targeting the folate receptor alpha (FRα) and has demonstrated promising single agent activity and a favorable toxicity profile in FRα-positive, platinum-resistant, epithelial ovarian cancer (EOC). "

01/01/2021 - "A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer."
01/01/2019 - "Herein, we developed a zirconium-89 (89Zr)-radiolabeled M9346A (89Zr-M9346A) as an immuno-positron emission tomography (immuno-PET) radiotracer to evaluate FRα expression in triple-negative breast cancer (TNBC) patients, providing a novel means to guide intervention with therapeutic IMGN853. "
01/01/2019 - "Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer."